Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

1920 - TRIANgLE study (JCOG1510): A phase III study of tri-modality combination therapy with induction docetaxel (DOC), cisplatin (CDDP), 5-fluorouracil (FU) (DCF) vs definitive chemoradiotherapy (dCRT) for locally advanced unresectable squamous cell carcinoma (SCC) of the thoracic esophagus

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Cytotoxic Therapy

Tumour Site

Oesophageal Cancer

Presenters

hiroyuki Daiko

Citation

Annals of Oncology (2018) 29 (suppl_8): viii205-viii270. 10.1093/annonc/mdy282

Authors

H. Daiko1, H. Hara2, H. Ogawa3, K. Hori4, J. Mizusawa5, S. Ozawa6, M. Takagi7, M. Tanaka8, H. Baba9, Y. Shirakawa10, M. Tsuda11, S. Nakagawa12, H. Takeuchi13, T. Abe14, Y. Ito15, T. Kojima16, T. Kadota5, H. Fukuda5, K. Kato17, Y. Kitagawa18

Author affiliations

  • 1 Esophageal Surgery Division, National Cancer Center Hospital, 104-0045 - Tokyo/JP
  • 2 Department Of Gastroenterology, Saitama Cancer Center, 362-0806 - saitama/JP
  • 3 Division Of Radiation And Proton Therapy Center, Shizuoka Cancer Center, Shizuoka/JP
  • 4 Department Of Gastroenterology And Endoscopy, National Cancer Center Hospital East, 277-8577 - Kashiwa/JP
  • 5 Jcog Data Center/ Operations Office, National Cancer Center, Tokyo/JP
  • 6 Department Of Gastroenterological Surgery, Tokai University School of Medicine, kanagawa/JP
  • 7 Department Of Gastroenterological Surgery, Shizuoka General Hospital, Shizuoka/JP
  • 8 Department Of Radiation oncology, Osaka City General Hospital, Osaka/JP
  • 9 Department Of Gastroenterological Surgery, Graduate School Of Life Sciences, Kumamoto University, 860-8556 - Kumamoto/JP
  • 10 Department Of Gastroenterological Surgery, Dentistry And Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Okayama/JP
  • 11 Department Of Gastroenterological Oncology, Hyogo Cancer Center, 673-8558 - Hyogo/JP
  • 12 Department Of Gastroenterological Surgery, Niigata Cancer Center Hospital, Niigata/JP
  • 13 Department Of Surgery, Hamamatsu University School of Medicine, Hamamatsu/JP
  • 14 Department Of Gastroenterological Surgery, Aichi Cancer Center Hospital, Nagoya/JP
  • 15 Department Of Radiation oncology, Showa University School of Medicine, Tokyo/JP
  • 16 Department Of Gastroenterology And Gastrointestinal Oncology, National Cancer Center Hospital East, 277-8577 - Kashiwa/JP
  • 17 Department Of Gastroenterology And Gastrointestinal Oncology, National Cancer Center Hospital, 104-0045 - Tokyo/JP
  • 18 Department Of Surgery, Keio University School of Medicine, 160-8582 - Tokyo/JP
More

Resources

Abstract 1920

Background

Although standard treatment for locally advanced unresectable esophageal SCC (LAUEC) has been dCRT consisted of CDDP plus FU, treatment outcome is limited. In the phase II trial of induction chemotherapy (Cx) with DCF followed by conversion surgery (CS) or dCRT plus CS for patients (pts) with LAUEC, 39.6% of pts received R0 resection via CS and achieved better 3-year overall survival (OS) of 71.4% with manageable toxicity.

Trial design

Eligibility criteria include as follows; histologically proven SCC, cT4b or cT3 but highly suspicious of cT4b and/or unresectable lymph nodes metastasis (LNM) invading to adjacent organs, no distant metastasis except for supraclavicular LNM, age 20 to 75, and performance status 0-1. Pts are randomized into following two arms stratified by institution, invasion to adjacent organs (definitive versus suspicious) and supraclavicular LNM (yes versus no). Pts in arm A receive dCRT consisted of CDDP (70 mg/m2/day, days 1 and 29) and FU (700 mg/m2/day, days 1-4 and 29-32, civ) with concurrent radiotherapy (60 Gy/30 fr) followed by additional Cx (CDDP [80 mg/m2/day, day 1 and 29] and FU [800 mg/m2/day, days 1-5 and 29-33, civ]). Pts in arm B receive 3 courses of DCF (DOC [70 mg/m2, day 1], CDDP [70 mg/m2, day 1] and FU [750 mg/m2, days 1–5] every 3 weeks) followed by CS if converted to be resectable, or dCRT same as Arm A if not converted to be resectable based on the radiological evaluation. Salvage surgery or endoscopic resection are acceptable in arm A (if residual, progressive, or recurring after dCRT) and in arm B (if converted to be resectable during or after dCRT). Primary endpoint is OS to confirm the superiority of arm B. We assumed 3-year OS with arm A to be 30% and expected a 12% increase for arm B. The planned sample size was calculated as a total of 230 pts (115 pts per arm) with a one-sided alpha of 5%, power of 70%, an accrual period of 4.5 years, and a follow-up period of 3 years. This trial was registered with UMIN-CTR, number UMIN000031165 and started in February 2018.

Clinical trial identification

UMIN000031165.

Legal entity responsible for the study

Japan Clinical Oncology Group: JCOG.

Funding

Japan Agency for Medical Research and Development (AMED).

Editorial Acknowledgement

Disclosure

H. Daiko, H. Ogawa, K. Hori, J. Mizusawa, S. Ozawa, M. Takagi, M. Tanaka, H. Baba, Y. Shirakawa, M. Tsuda, S. Nakagawa, H. Takeuchi, T. Abe, Y. Ito, T. Kadota, H. Fukuda: Japan Agency for Medical Research and Development (AMED), Ministry of Health, Labour and Welfare, Japan H. Hara: Japan Agency for Medical Research and Development (AMED), Ministry of Health, Labour and Welfare, Japan, Astrazeneca, Chugai, Merck Serono, MSD, Ono, Taiho, Takeda, Boehringer, Dainippon Sumitomo, Daiichi sankyo, Lilly, Pfizer, LSK Biopharma, Eisai, Incyte T. Kojima: Japan Agency for Medical Research and Development (AMED), Ministry of Health, Labour and Welfare, Japan, Shionogi, Ono, MSD, Oncolysis BioPharma, Astellas Amgen BioPharma K. Kato: Ono Pharmaceuticals, Merck and Co., Merck Serona, Shionogi Co and Ltd., Japan Agency for Medical Research and Development (AMED), Ministry of Health, Labour and Welfare, Japan Y. Kitagawa: Japan Agency for Medical Research and Development (AMED), Ministry of Health, Labour and Welfare, Japan, Kyowa hakko kirin, Takeda, Yakult honsya, Daiichi-sankyo.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.